47 articles with Centogene
Supporting rare disease diagnosis, education, and clinical research
CENTOGENE revealed the growth in its knowledge-base of rare hereditary diseases.
Driving personalized, immune-based therapy to target patients’ own immune responses
CENTOGENE biomarker measures lyso-Gb1 levels in children
Variant Prioritization Tool Driven by World’s Largest Curated Mutation Database
Research findings may provide deeper understanding on the role of genes that can contribute to development of Hypophosphatasia
In a whitepaper released, CENTOGENE provided an update on its induced pluripotent stem cells program.
CENTOGENE welcomed Germany’s Chancellor Dr. Angela Merkel to its headquarters together with Manuela Schwesig, Minister-President of Mecklenburg-Vorpommern.
One of the largest, most ethnically diverse studies of Parkinson’s disease to uncover the genetic basis of one of the most common neurodegenerative disorders
CENTOGENE announced the expansion of its executive leadership team with the appointment of Sun Kim in Boston, MA asChief Strategy & Investor Relations Officer.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners
Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions
CENTOGENE announces the appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman
CENTOGENE announced that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.
Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)
CENTOGENE Develops New Validation Framework to Optimize Specificity and Sensitivity in Whole Exome Sequencing-Based Diagnostics
Since NGS introduces a relevant number of false positives and false negatives, CENTOGENE has determined how to optimize the use of orthogonal Sanger sequencing of variants in parallel when looking at borderline cases.
Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development
CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year
2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases - driving momentum into 2019
CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development